Abstract

Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration

Author(s): Dib Jean G, Abdulmohsin Saud

Issue: Jan/Feb 2008 - Compounding for Hospice and Cancer Patients

Page(s): 8-14

Download in electronic PDF format for $75
  • Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Page 1
  • Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Page 2
  • Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Page 3
  • Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Page 4
  • Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Page 5
  • Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Page 6
  • Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Page 7

Abstract

Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, is used in the treatment of cancer. It was the first clinically available angiogenesis inhibitor in the U.S. Recently, bevacizumab has been used by ophthalmologists in the intravitreal treatment of choroidal neovascularization in agerelated macular degeneration. Since all published trials were less than one year in duration, including follow up, no conclusion can be drawn about the long-term safety and efficacy of intravitreal bevacizumab. In open-label studies, however, intravitreal bevacizumab has yielded marked improvements in visual acuity and central retinal thickness. Compounding pharmacists who are validated in aseptic compounding can prepare intravitreal bevacizumab from the available preservative-free phosphate-buffered intravenous solution using strict aseptic technique.

Related Keywords

  • formulations
  • bevacizumab
  • monoclonal antibody
  • vascular endothelial growth factor
  • VEGF
  • intravitreal administration
  • vitreous
  • eye
  • ophthalmic disorders
  • choroidal neovascularization
  • aging
  • macular degeneration
  • vision loss
  • visual acuity
  • retinal thickness
  • aseptic compounding
  • sterile preparation
  • blood vessels
  • angiogenesis
  • antiangiogenesis
  • drug costs

Related Categories

  • FORMULATIONS
  • GERIATRICS
  • OPHTHALMICS
  • DOSAGE FORMS/DRUG CARRIERS
  • PROFESSIONAL ISSUES

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 2008
Pg. 8-14
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration
Author(s): Dib Jean G, Abdulmohsin Saud
Jan/Feb 2015
Pg. 70-72
Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration
Author(s): Pereboom Marieke, Becker Matthijs L, Amenchar Mostapha, Verweij Sjoerd L, van der Hoeven Ruud TM, Mulder Inge J
May/Jun 2003
Pg. 170-174
Five Compounds for Treating Diabetes-Related Conditions
Author(s): Meece Jerry
Nov/Dec 2022
Pg. 446-466
Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Author(s): Allen Loyd V Jr
Jul/Aug 2022
Pg. 330-335
Physicochemical and Microbiological Stability of Vancomycin 10-mg/mL Intravitreal Syringes
Author(s): Bartoll Aaron Puplà, Bellés Medall Maria Dolores, Peñarrocha Josep Edo, Escrig Laura Solaz, Clemente Ruben Eguren, Azuara Julia Bodega, Piqueres Raul Ferrando
Jan/Feb 2013
Pg. 74-85
View Sample
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women
Author(s): Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K
Sep/Oct 2014
Pg. 418-426
Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation
Author(s): Robert Marie-Claude, Spurr-Michaud Sandra, Frenette Mathieu, Young David, Gipson Ilene K, Dohlman Claes H
Jan/Feb 2017
Pg. 62
Infliximab 1% Ophthalmic Solution
Author(s): Allen Loyd V Jr
Jul/Aug 2022
Pg. 336-341
Long-term Stability of Epitheliotropic Factors in Frozen Serum Eye Drops
Author(s): Sahyoun Jean-Yves, Cloutier Marc, Frenette Mathieu, Robert Marie-Claude
Jul/Aug 2011
Pg. 302-307
Treating Inner Ear Disorders with Intratympanic Drug Administration
Author(s): McElhiney Linda F
May/Jun 2012
Pg. 190-195
I See Colors: Using Vital Dyes in Diagnosing Ophthalmic Disease
Author(s): McElhiney Linda F
Nov/Dec 2009
Pg. 506-515
Autologous Eye Drops for the Treatment of Dry Eye and Neurotrophic Keratitis
Author(s): Mixon William, Angelle Patricea (Patsy), Chang Richard I
Nov/Dec 2020
Pg. 515-518
Development and Evaluation of an Anti-aging Cosmetic Formulation Exploring Antioxidant Potential of Vitis vinifera L.
Author(s): Carneiro Jaqueline, Marques Gonçalves Melissa, Vicente Pereira Airton
Sep/Oct 2016
Pg. 399-404
Basics of Sterile Compounding: Ophthalmic Preparations, Part 1: Ophthalmic Solutions
Author(s): Allen Loyd V Jr
Nov/Dec 2016
Pg. 495-500
Basics of Sterile Compounding: Ophthalmic Preparations, Part 2: Suspensions and Ointments
Author(s): Allen Loyd V Jr
Nov/Dec 2009
Pg. 540-543
Quality-Control Analytical Methods: Applications and Sterility of Autologous Eye Drops
Author(s): Reed-Kane Dana, Carlson Rachel A, Kupiec Thomas C, Vu Nicole
Sep/Oct 2019
Pg. 418-421
Measurement of Free Iodine in Different Formulations of Povidone-Iodine Eye Drops 5%
Author(s): Berisa Prado Silvia, Riestra Ayora Ana Cristina, Trelles Campa Adrián
Jan/Feb 2024
Pg. 6-14
Treatment Options for Male Hypogonadism
Author(s): Biundo Bruce
Jul/Aug 2018
Pg. 268
PreScription: Factors Related to Drug Waste and Pharmacy Solutions
Author(s): Allen Loyd V Jr
Sep/Oct 2010
Pg. 421
Three Fortified Ophthalmic Solutions: Amikacin 5% Ophthalmic Solution; Ceftazidime 5% Ophthalmic Solution; Vancomycin 5% Ophthalmic Solution
Author(s): Allen Loyd V Jr